Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report

SMARCA4‐deficient thoracic sarcoma (SMARCA4‐DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4‐DTS have not yet been developed. Most recently, anti‐programmed cell death 1 receptor (PD‐1) blockade h...

Descripción completa

Detalles Bibliográficos
Autores principales: Takada, Kohichi, Sugita, Shintaro, Murase, Kazuyuki, Kikuchi, Tomoki, Oomori, Ginji, Ito, Ryo, Hayasaka, Naotaka, Miyanishi, Koji, Iyama, Satoshi, Ikeda, Hiroshi, Kobune, Masayoshi, Emori, Makoto, Kato, Junji, Hasegawa, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885443/
https://www.ncbi.nlm.nih.gov/pubmed/31617320
http://dx.doi.org/10.1111/1759-7714.13215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885443/
https://www.ncbi.nlm.nih.gov/pubmed/31617320
http://dx.doi.org/10.1111/1759-7714.13215

Ejemplares similares